[Bdelloid rotifers (Rotifera, Bdelloidea) as a component of soil and land biocenoses]. / Bdelloidnye kolovratki (Rotifera, Bdelloidea) kak komponent pochvennykh i nazemnykh biotsenozov.

Morphological, physiological, and ecological adaptations of bdelloid rotifers (phylum Rotifera, class Bdelloidea) to the conditions of soil and land biocenoses are presented. The morphological structures, obligate parthenogenesis, and anhydrobiosis allowed these rotifers to colonize various semiaquatic areas with sharp fluctuations of environmental conditions: edaphon, coniferous and deciduous litters, mosses, and lichens. The role of bdelloid rotifers in the food web and environmental indication was mentioned. The controversial problems of the origin of this group of worms were broached.

[Phenomenon of obligate parthenogenesis in rotifer (Rotifera, Bdelloida)]. / Fenomen obligatnogo partenogeneza u kolovratok (Rotifera, Bdelloida).

A comparative analysis of biological and morphological organization of obligate parthenogenous bdelloids and heterogonic monogononts clarifies the specificity of bdelloids' environmental adaptation and variability. It is shown that phenotypic polymorphism of bdelloids differs from that of monogononts. The heterogonic Monogononta are characterized by tremendous phenotypic diversity in body structure adapted to different biotopes in continental waters. This diversity is reflected also in structure of corona and mastax used as major criteria for definition of high range taxa (classes, orders). The polymorphism of bdelloids manifests itself in variability of tiny morphological structures connected with living in restricted volumes of water, mainly in terrestrial biotopes. Being isolated from other Rotifera at the first stages of evolution, bdelloids have been specialized for living under extremely unstable terrestrial conditions that led to the development of anhydrobiosis and loss of amphimixis. Variability of bdelloids is not connected with characters of high taxonomic ranks and has principally different nature in comparison with monogononts. Tempo of specialization seems to be slower in obligate parthenogenous rotifers than in heterogonic ones.

[Cost per responder associated with romiplostim and rituximab treatment for adult primary immune thrombocytopenia in France]. / Coût par patient répondeur associé au traitement du purpura thrombopénique immunologique primaire par romiplostim et rituximab chez l'adulte en France.

PURPOSE OF THE STUDY: This analysis compared the response rates and cost per responder associated with romiplostim and rituximab in adult immune thrombocytopenia from the French National Health System payer perspective. METHODS: A decision analytic model was developed to estimate the cost per patient and per responder of treating adult immune thrombocytopenia patients with romiplostim versus rituximab over 6 months. A systematic literature review identified phase 3 randomized controlled trials. Published response rates were extracted (response definition: ≥50×10(9) platelets/liter). Resource utilization was based on French and international treatment guidelines, and clinical expert opinion. Unit costs were derived from literature and French reimbursement lists, and included the costs of routine physician visits, treatment administration, and emergency care. Non-responders incurred bleeding-related event costs. RESULTS: The literature review identified a phase 3 randomized controlled trial for romiplostim with a response rate of 83%. Due to a lack of phase 3 randomized controlled trials for rituximab, a systematic review of studies was selected as the best source, reporting a response rate of 62.5%. Romiplostim and rituximab were associated with similar treatment costs, with an estimated cost per patient for romiplostim of €17,456 and €17,068 for rituximab. Rituximab resulted in a 30% higher cost per responder (€27,308 for rituximab versus €21,031 for romiplostim). Romiplostim use reduced drug administration, intravenous immunoglobulin, and bleeding-related hospitalization costs compared to rituximab. CONCLUSIONS: Due to its high efficacy leading to lower bleeding-related costs, romiplostim represents an efficient use of resources for adult immune thrombocytopenia patients in the French healthcare system.